Advertisement

Medical Oncology

, Volume 28, Issue 3, pp 682–688 | Cite as

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

  • Chuan-Yong Mu
  • Jian-An HuangEmail author
  • Ying Chen
  • Cheng Chen
  • Xue-Guang Zhang
Original Paper

Abstract

The immunohistochemical analysis was used to evaluate the expression of PD-L1 in 109 non-small cell lung cancer (NSCLC) tissues and para-tumor tissues. Associations between expressed PD-L1 and tumor histological types, degree of differentiation, and lymph node metastasis were calculated, and overall survival was assessed. Meanwhile, immunohistochemistry and immunofluorescence double labeling technique were performed to detect the expressions of PD-L1, CD1α, and CD83 on TIDC of 20 lung cancer tissues, and the expression of PD-L1 in CD1α+DCs and CD83+DCs and their significances were also explored. We found that the expression rate of PD-L1 in NSCLC was associated with histological types and overall survival. Patients with either adenocarcinoma or survival time after surgery less than 3 years showed higher expression rate of PD-L1. Furthermore, Cox model analysis indicated that PD-L1 might be regarded as a poor prognostic factor. PD-L1 could be also detected in CD1α+ immature DC in NSCLC, indicating that as a class of key anti-tumor immunocyte in tumor microenvironment, DC expressing PD-L1 itself might play an important role in keeping its immature status and contributing to tumor cells immune escape and disease progression.

Keywords

NSCLC Dendritic cells (DC) Programmed-death receptor ligands 1 (PD-L1) CD83 CD1α 

Notes

Acknowledgments

We would like to thank Haidong Xu (Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, USA) for critical reading of the manuscript, Prof. Yongquan Xue (The first affiliated hospital of Soochow University, China) for his fluorescence microscope technique support, and Dr. Jinfang Shen (Soochow University, China) for pathological support. This work was supported by the ‘‘Key Project of National Natural Science Foundation of China’’ (30770947), “135 Projects focus on Talent Foundation of Health Department of Jiangsu Province (RC2007075)” and “Medical Development Foundation of Jiangsu Province (H200712)”.

References

  1. 1.
    Yasumoto K, Hanagiri T, Takenoyama M. Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer. Gen Thorac Cardiovasc Surg. 2009;57:449–57.PubMedCrossRefGoogle Scholar
  2. 2.
    Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307–14.PubMedCrossRefGoogle Scholar
  3. 3.
    XU X, et al. Clinicopathological significance of major histocompatibility complex class I-related chain A and B expression in thyroid cancer. Clin Endocrinol. 2006;91:2704–12.CrossRefGoogle Scholar
  4. 4.
    Kaklamanis L, et al. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol. 1994;145:505–9.PubMedGoogle Scholar
  5. 5.
    Blank C, Brown I, Peterson AC. PD-L1/B7–H1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+T cells. Cancer Res. 2004;64:1140–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Mary E, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. Exp Med. 2006;203:883–95.CrossRefGoogle Scholar
  7. 7.
    Fabienne H, et al. Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. Blood. 2008;112:2149–55.CrossRefGoogle Scholar
  8. 8.
    Gabrilovich D. Mechanisms and functional significance of tumor-induced dendritic cell defects. Nat Rev Immunol. 2004;4:941–52.PubMedCrossRefGoogle Scholar
  9. 9.
    Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Olaussen KA, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.PubMedCrossRefGoogle Scholar
  11. 11.
    Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116–26.PubMedCrossRefGoogle Scholar
  13. 13.
    Chen C, et al. Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells. Immunol. 2007;212:159–65.Google Scholar
  14. 14.
    Wong RM, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007;19:1223–34.PubMedCrossRefGoogle Scholar
  15. 15.
    Tsushima F, et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T cell anergy. Blood. 2007;110:180–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Blank C, et al. Blockade of PD-L1 (B7–H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006;119:317–27.PubMedCrossRefGoogle Scholar
  17. 17.
    Brown JA, et al. Blockade of programmed death 1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170:1257–66.PubMedGoogle Scholar
  18. 18.
    Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.PubMedGoogle Scholar
  19. 19.
    Matthias S. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr Relat Cancer. 2006;13:779–95.CrossRefGoogle Scholar
  20. 20.
    Mary F, Barbara J. Dendritic cells: immune regulators in health and disease. Physiol Rev. 2002;82:97–130.Google Scholar
  21. 21.
    Zhou LJ, Thomas F. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. PNAS. 1996;93:2588–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Vakkila J, et al. A basis for distinguishing cultured dendritic cells and macrophages in cytospins and fixed sections. Pediatr Dev Pathol. 2005;8:43–51.PubMedCrossRefGoogle Scholar
  23. 23.
    Ivan P, Dominique B, Nathalie F. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. Immunol. 2007;178:2763–9.Google Scholar
  24. 24.
    Kim R, Emi M, Tanabe K. Functional roles of immature dendritic cells in impaired immunity of solid tumor and their targeted strategies for provoking tumor immunity. Clin Exp Immunol. 2006;146:189–96.PubMedCrossRefGoogle Scholar
  25. 25.
    Hyun K, et al. Down-regulation of cellular vascular endothelial growth factor (VEGF) levels induces differentiation of leukemic cells into leukemic-dendritic cells in patients with acute myeloid leukemia. Blood ASH (Annual Meeting Abstracts). 2005;106: 2226.Google Scholar
  26. 26.
    Boorjian SA, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008;14:4800–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Sergey V, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 2008;112:1822–31.CrossRefGoogle Scholar
  28. 28.
    Konishi J, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor—infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094–100.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Chuan-Yong Mu
    • 1
    • 2
  • Jian-An Huang
    • 1
    • 2
    Email author
  • Ying Chen
    • 3
  • Cheng Chen
    • 1
    • 2
  • Xue-Guang Zhang
    • 4
  1. 1.Respiratory DepartmentThe First Affiliated Hospital of Soochow UniversitySuzhouChina
  2. 2.Clinical Immunology Laboratory of Jiangsu ProvinceThe First Affiliated Hospital of Soochow UniversitySuzhouChina
  3. 3.Respiratory DepartmentSuzhou Municipal HospitalSuzhouChina
  4. 4.Biotechnology Research InstituteSoochow UniversitySuzhouChina

Personalised recommendations